Successful commercial manufacturing of T cell therapies is essential to assuring the timely delivery of efficacious products to patients. Adequate cell therapy workflows have been developed to support clinical trials and commercialized T cell therapies. However, the industry faces several key barriers that limit the capability to deliver the required volume of high-quality product for autologous therapies and developing allogeneic applications.
To address key industry challenges, the Gibco™ CTS™ DynaCellect™ Magnetic Separation System, along with the Gibco™ CTS™ DynaCellect™ Cell Isolation Kit (Cat. No. A52300) and Gibco™ CTS™ DynaCellect™ Bead Removal Kit (Cat. No. A52301), were developed. This cell processing platform provides an automated, closed, flexible, and scalable platform for T cell isolation and activation using magnetic beads.
Download the application note learn how the CTS DynaCellect system when used with Gibco™ CTS™ Dynabeads™ CD3/CD28 can help improve T cell isolation efficiency, cell viability, target cell recovery, and potential time savings.
